M
Mark Rosenbach
Researcher at Merck & Co.
Publications - 31
Citations - 3883
Mark Rosenbach is an academic researcher from Merck & Co.. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 21, co-authored 31 publications receiving 3694 citations. Previous affiliations of Mark Rosenbach include United States Military Academy.
Papers
More filters
Journal ArticleDOI
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.
Suzanne M. Mandala,Richard Hajdu,James D. Bergstrom,Elizabeth J. Quackenbush,Jenny Xie,James A. Milligan,Rosemary A. Thornton,Gan-Ju Shei,Deborah Card,CarolAnn Keohane,Mark Rosenbach,Jeffrey J. Hale,Christopher L. Lynch,Kathleen M. Rupprecht,William H. Parsons,Hugh Rosen +15 more
TL;DR: It is shown that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolites of the immunosuppressive agent FTY720.
Journal ArticleDOI
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
Maria L. Allende,Teiji Sasaki,Hiromichi Kawai,Ana Olivera,Yide Mi,Gerhild van Echten-Deckert,Richard Hajdu,Mark Rosenbach,Carol Ann Keohane,Suzanne M. Mandala,Sarah Spiegel,Richard L. Proia +11 more
TL;DR: The results with these Sphk1 null mice reveal that some key physiologic processes that require S1P receptor signaling, such as vascular development and proper lymphocyte distribution, can occur in the absence of SPHK1.
Journal ArticleDOI
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
Michael J. Forrest,S.-Y. Sun,Richard Hajdu,James D. Bergstrom,Deborah Card,George A. Doherty,Jeffrey J. Hale,Carol Ann Keohane,C. Meyers,James A. Milligan,Sander G. Mills,N. Nomura,Hugh Rosen,Mark Rosenbach,G.-J. Shei,I. I. Singer,M. Tian,S. West,V. White,Jenny Xie,Richard L. Proia,Suzanne M. Mandala +21 more
TL;DR: Three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compound potency on S 1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia versus brady Cardia and hypertension was consistent with affinity for S1 p1 relative to S1p3; and toxicity, brady cardia, and hypertension were absent in S1 P3-/- mice.
Journal ArticleDOI
Discovery of Novel Antifungal (1,3)-β-d-Glucan Synthase Inhibitors
Janet C. Onishi,Maria S. Meinz,John R. Thompson,James E. Curotto,Sarah Dreikorn,Mark Rosenbach,Cameron M. Douglas,George K. Abruzzo,Amy M. Flattery,Leopold Kong,Angeles Cabello,Francisca Vicente,Fernando Pelaez,Maria Teresa Diez,Isabel Martin,Gerald F. Bills,Robert A. Giacobbe,Anne W. Dombrowski,Robert E. Schwartz,Sandra A. Morris,Guy H. Harris,A. Tsipouras,Kenneth E. Wilson,Myra B. Kurtz +23 more
TL;DR: Results of natural-product screening by a series of newly developed methods has led to the identification of four acidic terpenoid (1,3)-β-d-glucan synthase inhibitors, which have limited oral bioavailability and in vitro antifungal activity comparable to that of L-733560, a close analogue of MK-0991.
Journal ArticleDOI
Khafrefungin, a Novel Inhibitor of Sphingolipid Synthesis
Suzanne M. Mandala,Rosemary A. Thornton,Mark Rosenbach,James A. Milligan,Margarita Garcia-Calvo,Herbert G. Bull,Myra B. Kurtz +6 more
TL;DR: Khafrefungin, which is composed of aldonic acid linked via an ester to a C22 modified alkyl chain, has fungicidal activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae.